Paris, 22 March 2016

Bristol-Myers Squibb and Gustave Roussy sign a strategic collaboration to accelerate research in immuno-oncology

Immuno-oncology is an innovative therapeutic approach aimed at harnessing the natural capabilities of the immune system to fight cancer by targeting the same pathways tumor cells use to evade recognition and destruction. Today, immuno-oncology is one of the most promising areas in cancer research.

Bristol-Myers Squibb and Gustave Roussy announced today the signature of an important scientific collaboration to advance immuno-oncology research. In joining forces, they endeavor to further explore the scientific and clinical understanding of the role of immunotherapy in treating cancer patients. The clinical evidence of the efficacy of immunotherapy to date supports further study of its potential as an option in treating advanced cancer diseases. And, this collaboration is only the start of this new chapter regarding investigational cancer treatments.

Complementing our vast internal R&D program with innovative collaborations with cutting-edge cancer centers such as Gustave Roussy is instrumental to our pioneering approach in immuno-oncology. The alliance that has now been formalized between Bristol-Myers Squibb and the Institute is part of the Immuno-Oncology “Global Expert Centers Initiative (GECI)”. Launched by Bristol-Myers Squibb in Europe, GECI has the objective of strengthening collaboration with the most innovative cancer treatment centers and thereby accelerating research. We are very honored that Gustave Roussy is now the first institute to join the GECI program,” said Fouad Namouni, MD, senior vice president, head of medical, Bristol-Myers Squibb.

Bristol-Myers Squibb is one of our important partners in deploying our Immunotherapy research program, which is a major priority for our institution. This new research approach, which has been used to study numerous types of different cancers, represents a true revolution for patients and is an undeniable pillar for development of future therapeutic strategies in oncology,” stated Professor Alexander Eggermont, General Director of Gustave Roussy.

The agreement concerns early access to innovative immunotherapy molecules developed by Bristol-Myers Squibb, in particular for phase I/II trials conducted in the Therapeutic Innovation and Early Trials Department (Département Innovation Thérapeutique et Essais Précoces, DITEP) at Gustave Roussy, as well as for phase II and III validation in different cancers. Gustave Roussy may also propose that Bristol-Myers Squibb support the trials through institutional promotion by contributing regimens or original patterns. The agreement also anticipates preclinical and translational studies, based on research programs by Gustave Roussy teams. A joint steering committee will ensure the advancement of projects.

Bristol-Myers Squibb and Gustave Roussy, pioneers in immuno-oncology research

Today, Gustave Roussy is a leading immuno-oncology research center in Europe and a pioneer in validating the efficacy of immunomodulator monoclonal antibodies.

Bristol-Myers Squibb has a vision for the future of cancer care that is focused on Immuno-Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy and targeted therapies for certain types of cancer.

The company has a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, many of which were discovered and developed by its scientists. The ongoing Immuno-Oncology clinical program is looking at broad patient populations, across multiple solid tumors and hematologic malignancies, and lines of therapy and histologies, with the intent of powering trials for overall survival and other important measures like durability of response. Bristol-Myers Squibb pioneered the research leading to the first regulatory approval for the combination of two Immuno-Oncology agents, and continues to study the role of combinations in cancer.

The company is also investigating other immune system pathways in the treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO, and LAG-3. These pathways may lead to potential new treatment options – in combination or monotherapy – to help patients fight different types of cancers.

Through this strategic partnership, Bristol-Myers Squibb and Gustave Roussy join forces to support scientific progress with the objective of significantly increasing the benefits for patients in terms of overall survival while improving their quality of life during their treatment.

Today, Gustave Roussy is a leading immuno-oncology research center in Europe and a pioneer in validating the efficacy of immunomodulator monoclonal antibodies.

PDF icon> Read the press release in PDF

Catégorie de la page: